At this time, I'd like to welcome everyone to the Biogen First Quarter 2025 Earnings ... which was the approval for the IV maintenance, which will allow us to reduce the dosing for patients ...

Tysabri (natalizumab) can be safe as a treatment for relapsing forms of MS during pregnancy or while breastfeeding, a study ...

Major players operating in the tysabri (natalizumab) market are Biogen Idec Inc., Sandoz International GmbH, and Polpharma Biologics. North America was the largest region in the tysabri ...

Major players operating in the tysabri (natalizumab) market are Biogen Idec Inc., Sandoz International GmbH, and Polpharma Biologics. North America was the largest region in the tysabri (natalizumab) ...

Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed. Natalizumab – best known as MS drug Tysabri - failed to show any benefits ...

Regulators in the US and Europe have started to review Novartis' biosimilar version of Biogen's big-selling multiple sclerosis therapy Tysabri, which could reach the market next year. If approved ...

At this time, I'd like to welcome everyone to the Biogen first quarter 2025 earnings ... which was the approval for the IV maintenance, which will allow us to reduce the dosing for patients ...

Biogen Inc. (BIIB), currently valued at $18 billion by market capitalization, reported stronger-than-expected earnings for the first quarter of 2025, with earnings per share (EPS) of $3.02 ...